Oscient reiterated at market outperform by JMP

Oscient Pharmaceuticals Corp. was reiterated at market outperform by JMP Securities analyst Adam Cutler. For the week ended May 5, NDC reported that Factive total prescriptions were 5,677 (5,481 new), or 0.90% of weekly prescriptions for the quinolone class of antibiotics, compared with the previous week's 5,847 total prescriptions (5,662 new), or 0.92% of weekly prescriptions from the quinolone class. About 27,826 Factive prescriptions have been written in second quarter through May 5, generating about $2.5 million in revenue. Total Testim (Auxilium Pharmaceuticals) scripts for the week ended May 5 were 5,803 compared with 5,574 for the previous week. Shares of the Waltham, Mass., biopharmaceutical company were down 6 cents, or 4.62%, at $1.24 on volume of 612,059 shares versus the three-month running average of 455,335 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.